Technology
Health
Biotechnology

SELLAS Life Sciences

$0.605
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.1997 (-25.60%) Today
+$0.0246 (4.24%) After Hours

Why Robinhood?

You can buy or sell SLS and other stocks, options, ETFs, and crypto commission-free!

About

SELLAS Life Sciences Group, Inc. operates as a clinical stage biopharmaceutical company, which focuses on the development and commercialization of novel cancer immunotherapeutics for cancer indications. Its product galinpepimut-S, or GPS, is an immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, which targets the Wilms tumor 1, or WT1, protein. Read More Its products include galinpepimut-S and nelipepimut-S. The company was founded on April 3, 2006 and is headquartered in New York, NY.

Employees
8
Headquarters
New York, New York
Founded
2006
Market Cap
12.78M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
844.19K
High Today
$0.7013
Low Today
$0.58
Open Price
$0.66
Volume
774.41K
52 Week High
$6.97
52 Week Low
$0.58

Collections

Technology
Health
Biotechnology
Cancer Prevention
Medical
Biopharmaceutical
Pharmaceutical
US

Earnings

-$0.40
-$0.33
-$0.27
-$0.20
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.20 per share
Actual
-$0.22 per share

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.